Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers

By Investor's Business Daily | Aug 28, 2024 at 08:17 AM EST

Neurocrine Biosciences' positive phase 2 trial results for a schizophrenia treatment fell short compared to competitors like Bristol Myers Squibb. Despite this setback, an expanded final-stage trial is planned, bringing the industry closer to a new treatment for schizophrenia after 70 years.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.